This page shows what was measured, who it was measured in, and what that does not settle.
What Fenofibrate does in the body
Triglyceride (TG) levels
From the FDA-approved label: The active moiety of fenofibrate tablets is fenofibric acid. The pharmacological effects of fenofibric acid in both animals and humans have been extensively studied through oral administration of fenofibrate. The lipid-modifying effects of fenofibric acid seen in clinical practice have been explained in vivo in transgenic mice and in vitro in human hepatocyte cultures by the activation of peroxisome proliferator activated receptor α (PPARα). Through this mechanism, fenofibrate increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apoprotein C-III (an inhibitor of lipoprotein lipase activity).
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
RNAWiki has not recorded a supervision or regulatory status for this substance.
What the registries record it as
The substance registry classes this as chemical.
FDA substance registry · U202363UOS · read 2026-08-29
Its recorded molecular formula is C20H21O4Cl, weighing 360.83.
US prescribing information · d9be3ae3-6da9-47fd-bcfd-e561b9d585ca · read 2026-08-30
Where each sentence above came from
No recorded sentence describes the change this makes in a way that stands on its own. The page opens with what it is taken for instead, and the recorded explanation follows below.
Shown as the opening line on this page.
No statement of the main limit is recorded.
The four opening statements run to 113 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Stand-in result
A stand-in result is a number measured because the real result takes too long.
A picture of it, and where the picture fails
It is like judging a journey by the speedometer rather than by arriving.
Where that stops being true. Speed does predict arrival. Many stand-in results do not predict the real one.
What people get wrong. A stand-in result is often reported as the result itself.
A surrogate endpoint substituted for a clinical endpoint, valid only where the substitution has been shown to hold.
Enzyme
An enzyme is a protein that speeds up one chemical change.
A picture of it, and where the picture fails
An enzyme is like a machine on a production line doing one cut.
Where that stops being true. A machine is switched on and off by a person. Enzymes are controlled by the cell.
What people get wrong. Enzymes are thought to be used up. They are not; they work again and again.
A catalytic protein that lowers the activation energy of a specific reaction.
Receptor
A receptor is a part of a cell that a signal fits into.
A picture of it, and where the picture fails
A receptor is like a lock waiting for one key.
Where that stops being true. A lock either opens or does not. A receptor can be half-triggered, or worn out.
What people get wrong. Fitting a receptor is read as causing a benefit. It causes a step, and nothing more.
A protein that binds a specific ligand and converts that binding into a cellular response.
Pathway
A pathway is a chain of steps inside a cell, each one setting off the next.
A picture of it, and where the picture fails
A pathway is like a row of dominoes.
Where that stops being true. Dominoes fall one way. Pathways loop back and can switch themselves off.
What people get wrong. Changing one step is read as changing the outcome. Other steps often absorb it.
An ordered series of molecular interactions producing a defined cellular change.
What happened in people◇Read from sources, not yet reviewed
What was measured, goal by goal
One row for each goal a registered study measured something for. One column for each kind of thing that could be measured.
Registered studies list 40 outcome measures that RNAWiki could read. A registered study says what someone planned to measure. It does not say what they found. 0 of the matched studies tested this substance, and 0 posted a result.
There is no single score. A strong test result and a weak life result are different facts.
Goals down the side, kinds of measurement across the top. Each cell says what kind of thing was registered, not what was found.
Goal
Life outcome
What a body can do
How a person feels
A test result
A step in the body
Harms
How long
Who was studied
Cholesterol
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
△Only a number moved15 registered test measure.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Blood sugar
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
△Only a number moved5 registered test measure.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Which registered measures put each goal on this table
Cholesterol
ldl c and non hdl c levels; pre and post intervention triglyceride levels; pre and post intervention ldl cholesterol levels; pre and post intervention hdl cholesterol levels; triglycerides; non hdl c; hdl c; total cholesterol
Sorted by fixed word lists, version v1. A name the rules do not recognise stays unsorted rather than moving to the nearest column.
What each mark on this table means
∅ Nothing in the sources checked
No registered study lists a life outcome for this goal.
△ Only a number moved
15 registered test measure.
— Not recorded
Harms were not a registered measure for this goal.
… Waiting for a reviewer
Who was studied is listed further down the page.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.
✗ The study did not show it
Who was studied
NCT00000620
How many people
10251
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Composite of CV Death, Nonfatal MI (Including Silent MI), Nonfatal Stroke, Coronary Revascularization, or Unstable Angina Determined to be Caused by Myocardial Ischemia by Invasive / Non-invasive Testing and Requiring Emergent Hospitalization.
✗ The study did not show it
Who was studied
NCT01492361
How many people
8179
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
major adverse cardiovascular events and diabetic microvascular events for 48 months
✗ The study did not show it
Who was studied
NCT06293417
How many people
3958
Study design
Not applicable
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Number of Participants With Progression of Diabetic Retinopathy of at Least 3 Stages on the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale, or Development of Proliferative Diabetic Retinopathy Necessitating Photocoagulation Therapy or Vitrectomy
✗ The study did not show it
Who was studied
NCT00542178
How many people
3472
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Rate of unintended pregnancy
✗ The study did not show it
Who was studied
NCT06024616
How many people
2400
Study design
Not applicable
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
The percentage of normalized patients at V4 (fasting glucose < 6.1 mmol/L, TG < 1.69 mmol/L and HDL-C >= 1.03 mmol/L in males and >= 1.29 mmol/L in females)
✗ The study did not show it
Who was studied
NCT00703755
How many people
2288
Study design
Phase 2
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What happened in people◇Read from sources, not yet reviewed
How close this is to real life
The top step is something a person would feel or care about. The bottom is a guess from software. Filled steps are where evidence exists for this substance.
□Living longer, or avoiding a major eventNo evidence recorded. Death, a heart attack, a stroke, a hospital stay.0 registered measures of this kind. 3 written-up studies measured this and did not show a benefit.
□What a body can do day to dayNo evidence recorded. Walking, dressing, breathing, recovering.No registered study measures this.
□Measured performanceNo evidence recorded. How much was lifted, how far was run, how fast.No registered study measures this.
□Symptoms and quality of lifeNo evidence recorded. Pain, tiredness, mood, sleep, as the person rated it.No registered study measures this.
■A number that stands in for healthEvidence recorded. Cholesterol, blood sugar, bone density. A stand-in, not the thing itself.24 registered measures of this kind.
■A step measured inside a personEvidence recorded. Something measured in human tissue or human cells.1 registered measure inside human tissue.
■AnimalsEvidence recorded. Mice, rats, dogs. Useful for ideas, not proof about people.Stored records in Mouse, Rat. A result in animals says what to test next. It does not say what happens in people.
■Cells in a dishEvidence recorded. Cells or chemistry on a bench, far from a whole body.Stored mechanism abstracts describe steps measured in cells or tissue.
□A guess from softwareNo evidence recorded. Nobody measured it. RNAWiki never publishes one as a finding.RNAWiki stores no prediction for this record. Software can suggest a link. RNAWiki does not publish one as a finding.
Higher on these steps means closer to something a person would feel. It does not mean better done.
What it would be like to take◇Read from sources, not yet reviewed
Felt, measured, or meaningful
Three different things that get called the same word. Registered studies measured all three, and mixing them is how a blood test becomes a health claim.
Felt
Things a person could notice without a test.
No registered study measured anything of this kind.
Measured
Things only a test, a scale or a device shows.
ldl c and non hdl c levels
pre and post intervention triglyceride levels
pre and post intervention ldl cholesterol levels
pre and post intervention hdl cholesterol levels
triglycerides
non hdl c
hdl c
total cholesterol
total cholesterol hdl c
fasting plasma low density lipoprotein cholesterol
and 15 more.
Meaningful
Things that change how a life goes, not only a number.
No registered study measured anything of this kind.
A registered study says what someone planned to measure. It does not say what they found. A number moving is not the same as a life going better. The two are shown apart here.
Felt, but not shown to help. A person notices a change. No study showed it leads anywhere good.
Measured, but not felt. A number moves. The person notices nothing. Both can be true.
Measured, but not shown to matter. A number moves in the good direction. Nobody showed that lives went better.
Matters, but takes years. The result that counts may take longer than anyone would keep watching.
Names that fit none of the three (15)
liver/spleen at 6 months
therapy completion rate
auc0 t simvastatin
auc0 t simvastatin acid
auc0 t total ezetimibe
auc0 t rosuvastatin
auc0 t fenofibric acid
auc0 t atorvastatin acid
auc0 t nicotinic acid
auc0 t nicotinuric acid
endothelial function
bioequivalence
area under the curve of fenofibric acid
fenofibratae pharmacokinetic parameter values
relative fmd
These are harms, study-process measures, or names the rules did not recognise. They are shown rather than dropped.
What it would be like to take◇Read from sources, not yet reviewed
How long anything takes
Nine different lengths of time that get confused with each other. None of them is worked out from another.
Before anything is noticed.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before a test result moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before performance moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
How long the result was watched.No finished study window is recorded for a study that tested this substance.
How long people took it.How long people actually took it is not stored. The study window is not the same thing.
How long people were followed.Follow-up length is not stored separately. It is never read off the study window, which would be a different thing.
How fast the body clears it. 20 hours hours
Read from the label, which states: “Elimination Fenofibric acid is eliminated with a half-life of 20 hours, allowing once daily administration of fenofibrate.”
How long effects linger.RNAWiki does not store this separately, and never works it out from another figure on this page.
Beyond the studies. Nothing is recorded about the long term.
The longest finished study sets the edge of what anyone measured.
A study window is not how long people took it, and neither is how long they were followed. Where RNAWiki holds only one of the three, it shows one.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
Fenofibrate tablets USP is indicated as adjunctive therapy to diet: • To reduce triglyceride (TG) levels in adults with severe hypertriglyceridemia (TG greater than or equal to 500 mg/dL). • To reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia when use of recommended LDL-C lowering therapy is not possible. Limitations of Use • Markedly elevated levels of serum TG (e.g.
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “The safety and effectiveness of fenofibrate have not been established in pediatric patients with severe hypertriglyceridemia or primary hyperlipidemia.”
US prescribing information · d9be3ae3-6da9-47fd-bcfd-e561b9d585ca · read 2026-08-30
On older people, the label states: “Assess renal function in geriatric patients and follow contraindications and dosing recommendations for patients with renal impairment [see Contraindications ( 4 ), Warnings and Precautions ( 5.3 , 5.4 ) and Use in Specific Populations ( 8.6 )] .”
US prescribing information · d9be3ae3-6da9-47fd-bcfd-e561b9d585ca · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary Limited available data with fenofibrate use in pregnant women are insufficient to determine a drug associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.”
US prescribing information · d9be3ae3-6da9-47fd-bcfd-e561b9d585ca · read 2026-08-30
On people who are breastfeeding, the label states: “Risk Summary There is no available information on the presence of fenofibrate in human milk, effects of the drug on the breastfed infant, or the effects on milk production.”
US prescribing information · d9be3ae3-6da9-47fd-bcfd-e561b9d585ca · read 2026-08-30
On people with reduced liver function, the label states: “The use of fenofibrate has not been evaluated in patients with hepatic impairment.”
US prescribing information · d9be3ae3-6da9-47fd-bcfd-e561b9d585ca · read 2026-08-30
On people with reduced kidney function, the label states: “Fenofibrate is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73m 2 ), including those with end-stage renal disease (ESRD) and those receiving dialysis.”
US prescribing information · d9be3ae3-6da9-47fd-bcfd-e561b9d585ca · read 2026-08-30
Where the result stopped carrying
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied for a different goal
The studies measured something else entirely.
On this record: Some registered studies measured things that match no goal on this page.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (10)
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Prescription only
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
RNAWiki has not recorded a supervision or regulatory status for this substance.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
No register row and no identity class settled the question.
No source is stored against this line.
What is in the pack
Sold as tablet, capsule, tablet, film coated, tablet, coated, given by the oral route.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take∅Nothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
∅Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Reports sent to a regulator
These are reports people sent to a regulator. They do not show the medicine caused the reaction.
Nobody counted how many people took the medicine and reported nothing.
The same event can be reported more than once, and many reports are incomplete.
News coverage, lawsuits and new warnings change how often people report.
A count is not a rate and not a risk.
Fenofibrate appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 1659 reaction mentions were counted. One report can name several reactions.
open-targets-adr · recorded 2026-06-24 · a recorded source, not a stored snapshot
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
229 products list this as an active ingredient in the United States drug directory. 229 of them contain it and nothing else.
FDA National Drug Code directory · 65862-768 · read 2026-08-29
They are sold as capsule, powder, tablet, tablet, coated and tablet, film coated, taken oral.
FDA National Drug Code directory · 65862-768 · read 2026-08-29
The regulator's established pharmacologic class for it is peroxisome proliferator receptor alpha agonist [epc].
FDA National Drug Code directory · 65862-768 · read 2026-08-29
135 published labels name it as an active ingredient. 135 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · d9be3ae3-6da9-47fd-bcfd-e561b9d585ca · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · d9be3ae3-6da9-47fd-bcfd-e561b9d585ca · read 2026-08-29
Fenofibrate is oral at 3 DOSAGE FORMS AND STRENGTHS Fenofibrate Tablets USP: • 48 mg: White to off-white oval shaped tablets debossed with "LU" on one side and "B21" on the other side. • 145 mg: White to off-white oval shaped tablets debossed…, recorded as fda label in effect 2026-07-16 in the United States.
US prescribing information · d9be3ae3-6da9-47fd-bcfd-e561b9d585ca · read 2026-08-30
Recorded price in US: 0.07792–16.95398 USD per one unit as the pricing file counts it — a tablet, capsule, patch or single item, across 105 priced products whose strengths and pack forms differ, as of 2026-08-26, paid by retail pharmacies buying the product, as surveyed by the Centers for Medicare & Medicaid Services. It is not a list price, an insurance price, or what anyone pays at a counter..
Recorded source · 2026-08-26 · read 2026-08-28
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
RNAWiki could not confidently classify this substance, so no self-experiment plan is offered.
Questions worth asking
Which of the trials of Fenofibrate studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Fenofibrate are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
How many documents were read
136 documents were read for this substance.
RNAWiki source record
136 of them state the same proteinBinding, and they agree.
RNAWiki source record
Where else this substance is registered
FDA substance identifier (UNII)
U202363UOS
RxNorm concept
477560
Checks this page had to pass
✓ Passed
Identity resolved
no open identity hold
✓ Passed
No unresolved merge across substance families
no quarantine open
✓ Passed
Every public sentence names a source
The opening statement carries the origin: Written into the record, not signed off.
✗ Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
✓ Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
✗ Not passed
Safety mode resolved
No register row and no identity class settled the question.
✓ Passed
Canonical metadata present
slug and display name present
What is missing or unclear◇Read from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
What the approval register records
55 approved applications cover products containing this substance. The earliest was NDA019304, approved 19931231 to ABBVIE.
This order is fixed in code and does not count clicks or time on the page.
What is not here
5 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
The path through the body — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (14)
Q1
What did Fenofibrate's largest trial (10251 people) and its longest (13 years) measure?
10251 people in Fenofibrate's largest registered study, 13 years in its longest registered window, measuring Shift in Myocardial substrate utilization in aging hearts. ClinicalTrials.gov · 2026-09-01
37 phase2, 36 phase3, 26 na, 26 phase4, 14 phase1, 6 na or unstated, 2 early phase1; NCT00000620; 2012-12. Last human test completed 2025, NCT05753267.
Interpretation These counts include studies where Fenofibrate was a comparison treatment, a background treatment or an exposure in an observational study, and the longest window may be a planned end date. Trial roles have not yet been classified for this record.
Show the evidence
phase2
37
phase3
36
na
26
phase4
26
phase1
14
na or unstated
6
2 more recorded rows
early phase1
2
Last recorded human testNCT05753267
2025-09-20
recorded 2026-09-01 · last checked 2026-09-04
Q2
From mouse to human: where has Fenofibrate shown lifespan?
Interpretation Shift in Myocardial substrate utilization in aging hearts — the recorded outcome words.
Show the evidence
mouse
lifespan
rat
mechanism-only
humanNCT00627653
mechanism-only; Shift in Myocardial substrate utilization in aging hearts; 136
recorded 2026-09-01 · last checked 2026-09-04
Q3
17 of Fenofibrate's trials stopped: accrual/recruitment, funding/business, other?
accrual/recruitment (9), funding/business (3) and other (5): Fenofibrate's stop wording, clustered. ClinicalTrials.gov · 2026-09-01
"Protocol drug change required new clinicaltrails.gov entry"; 17 of 136 registered studies
Show the evidence
Trial
NCT00252499
terminated; "Protocol drug change required new clinicaltrails.gov entry"
NCT00261352
terminated; "The development program has been terminated"
NCT00362765
terminated; "The study was prematurely terminated, due to difficulties in the recruitment of T2DM patients who are not under statin therapy at inclusion."
NCT00483210
withdrawn; "The study goals were accomplished by a similar study at UAMS. (W.J. Evans)"
NCT00491400
terminated; "Insufficient enrollment"
NCT00644592
terminated; "supply issues with the formulation of fenofibrate that was used."
11 further recorded trials
NCT00732485
withdrawn; "Principal Investigator Changed"
NCT00816829
terminated; "The study was prematurely terminated because of slow recruitment"
NCT00819910
terminated; "Slow recruitment and increase in deployment overseas limiting follow up"
NCT00884819
terminated; "Poor recruitment"
NCT01141296
withdrawn; "Lack of funding"
NCT01289639
terminated; "Low recruitment in intervention study. Baseline data published."
NCT01574131
terminated; "lost funding; Shriner Burn Hosp has revoked access to study records. No updates or results can be submitted"
NCT01965834
terminated; "Lack of adequate accrual."
NCT02452255
terminated; "Shriner's Burn Hospital closed the study and access to study-related data is unavailable. We are unable to submit the additional information or results-data"
NCT02965911
withdrawn; "No participants enrolled"
NCT05514119
terminated; "Low Enrollment"
recorded 2026-09-01 · last checked 2026-09-04
Q4
Human studies of Fenofibrate used Combination of Pravastatin 40 mg and Fenofibrate 160 mg — over how long?
Human studies of Fenofibrate used "Combination of Pravastatin 40 mg and Fenofibrate 160 mg". ClinicalTrials.gov · 2026-09-01
19 recorded entries; human; tablet, capsule; also "Fenofibrate 145mg PO QD", "Fenofibrate 160 mg tablet", "TriCor® 145mg tablets"
Show the evidence
human
NCT00459745
Combination of Pravastatin 40 mg and Fenofibrate 160 mg
NCT00470262
Fenofibrate 145mg PO QD
NCT00543647
tablet; Fenofibrate 160 mg tablet
NCT00613613
TriCor® 145mg tablets
NCT00775359
Fenofibrate 160 mg tablets
NCT00775827
fenofibrate 160 mg tablets
13 more recorded rows
humanNCT00960687
Fenofibrate (Tricor®) 145 mg Tablet
humanNCT01280604
Fenofibrate 54mg
humanNCT01674712
Fixed Combination of Fenofibrate/simvastatin 145/20 mg
humanNCT01674712
Fenofibrate 145 mg
humanNCT01674712
Fixed Combination of Fenofibrate/simvastatin 145/40 mg
humanNCT01752842
capsule; Sugar pill manufactured to mimic Fenofibrate 160 mg capsule
humanNCT01767610
micronized fenofibrate 160mg
humanNCT01767610
micronized fenofibrate 160mg plus pitavastatin Ca 2mg
Fenofibrate's half-life is 20 hours — which schedules were studied?
20 hours, the half-life Fenofibrate's label states. openfda-label · b6b5d74d-d418-4ada-8ccd-592b0f57b2ff · 2026-08-30
Show the evidence
half life
20 hours hours; Elimination Fenofibric acid is eliminated with a half-life of 20 hours, allowing once daily administration of fenofibrate.
bioavailability
Absorption The absolute bioavailability of fenofibrate cannot be determined as the compound is virtually insoluble in aqueous media suitable for injection.
metabolism
Metabolism Following oral administration, fenofibrate is rapidly hydrolyzed by esterases to the active metabolite, fenofibric acid; no unchanged fenofibrate is detected in plasma.
recorded 2026-08-30 · last checked 2026-09-04
Q6
Could one person measure Fenofibrate's effect on ldl c and non hdl c levels?
Ldl c and non hdl c levels: measured in Fenofibrate's trials.
Interpretation ldl c and non hdl c levels is the recorded endpoint.
Show the evidence
biomarkers
ldl c and non hdl c levels; 2026-09-01
pre and post intervention triglyceride levels; 2026-09-01
pre and post intervention ldl cholesterol levels; 2026-09-01
pre and post intervention hdl cholesterol levels; 2026-09-01
triglycerides; 2026-09-01
non hdl c; 2026-09-01
14 more recorded rows
biomarkers
hdl c; 2026-09-01
biomarkers
total cholesterol; 2026-09-01
biomarkers
total cholesterol hdl c; 2026-09-01
biomarkers
fasting plasma low density lipoprotein cholesterol; 2026-09-01
biomarkers
liver/spleen at 6 months; 2026-09-01
biomarkers
hepatic insulin sensitivity index; 2026-09-01
biomarkers
adipose tissue insulin sensitivity; 2026-09-01
biomarkers
skeletal muscle insulin sensitivity; 2026-09-01
biomarkers
effect of treatment on peak ldl particle size; 2026-09-01
biomarkers
therapy completion rate; 2026-09-01
biomarkers
auc0 t simvastatin; 2026-09-01
biomarkers
auc0 t simvastatin acid; 2026-09-01
biomarkers
auc0 t total ezetimibe; 2026-09-01
biomarkers
auc0 t rosuvastatin; 2026-09-01
half life
2026-09-04; halfLife; hours; 20 hours; 2026-08-30
human trials at or under30
37
smallest human trial
0; NCT00376285; PHASE1; the smallest recorded human enrolment at or below 30; the registry states no direction of its result; WITHDRAWN
Q7
Which of adipose tissue insulin sensitivity, area under the curve of fenofibric acid and auc0 t atorvastatin acid did Fenofibrate's trials measure?
adipose tissue insulin sensitivity, area under the curve of fenofibric acid and auc0 t atorvastatin acid lead 40 outcome terms across Fenofibrate's trials. ClinicalTrials.gov · 2026-09-01
Interpretation pre and post intervention hdl cholesterol levels, triglycerides, non hdl c, hdl c, total cholesterol and total cholesterol hdl c follow.
Show the evidence
ldl c and non hdl c levels
1
pre and post intervention triglyceride levels
1
pre and post intervention ldl cholesterol levels
1
pre and post intervention hdl cholesterol levels
1
triglycerides
1
non hdl c
1
14 more recorded rows
hdl c
1
total cholesterol
1
total cholesterol hdl c
1
fasting plasma low density lipoprotein cholesterol
1
liver/spleen at 6 months
1
hepatic insulin sensitivity index
1
adipose tissue insulin sensitivity
1
skeletal muscle insulin sensitivity
1
effect of treatment on peak ldl particle size
1
therapy completion rate
1
auc0 t simvastatin
1
auc0 t simvastatin acid
1
auc0 t total ezetimibe
1
auc0 t rosuvastatin
1
recorded 2026-09-01 · last checked 2026-09-04
Q8
Which of Fenofibrate's 15 ongoing trials reports first?
Occurrence of clinical significant retinopathy progression.; Worsening of diabetic retinopathy; latest 2035-12
Show the evidence
Trial
NCT01320345
"The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye."; n 412; "Occurrence of clinical significant retinopathy progression."; 2026-12
NCT04661358
"Fenofibrate for Prevention of DR Worsening"; n 563; "Worsening of diabetic retinopathy"; 2029-12
NCT04907084
"Serine and Fenofibrate Study in Patients With MacTel Type 2"; n 60; "Serum Deosxysphingolipid Levels"; 2024-03
NCT04929379
"A Pilot Study of Fenofibrate to Prevent Kidney Function Loss in Type 1 Diabetes"; n 40; "Baseline-adjusted iGFR at 8 weeks after randomization"; 2026-10-31
NCT05749822
"Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis"; n 104; "Percentage of patients with biochemical response"; 2027-12-31
NCT06174402
"Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis"; n 184; "Percentage of patients with biochemical response"; 2026-12-31
9 further recorded trials
NCT06191133
"Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma"; n 24; "Change in p53 levels"; 2026-12-30
NCT06365424
"Fenofibrate in Patients With Primary Biliary Cholangitis (PBC)"; n 117; "Treatment emergent adverse events (TEAEs)"; 2027-04
NCT06623539
"Efficacy and Safety of Pemafibrate for Nonalcoholic Fatty Liver Disease"; n 360; "Change in ALT level"; 2026-03
NCT06755151
"Fenofibrate in Primary Biliary Cholangitis: a Real World Study"; n 300; "Treatment emergent adverse events (TEAEs)"; 2035-12
NCT06858332
"Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia"; n 2382; "Percentage of patients (%) with Lp(a) ≥125 nmol/L"; 2027-09-30
NCT06905054
"Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation"; n 80; "To determine the incidence of rPSC in LT recipients treated with fenofibrate, compared with an untreated control cohort."; 2028-07-01
NCT07104201
"Fenofibrate in Subjects With Primary Biliary Cholangitis (PBC)"; n 15; "Treatment emergent adverse events (TEAEs)"; 2035-03
NCT07296458
"FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy"; n 132; "Percentage of Participants with Normal ALP level"; 2028-12-31
NCT07572552
"Clinical Study Evaluating the Efficacy and Safety of Fenofibrates Versus Silymarin in Adult Patients With Sepsis"; n 66; "change in the measured biological markers (TNF-α, MDA, and IL-10)"; 2028-04
recorded 2026-09-01 · last checked 2026-09-04
Q9
Which 41 trials of Fenofibrate posted no result?
Posted no result
41 of 41 completed trials
Registrations
NCT00422396, NCT00775359, NCT00775827, NCT00543647, NCT00006412 and NCT00304993, and 35 more
Completion dates
oldest 2002-04; newest 2024-08-05
Show the evidence
Trial
NCT00422396
2002-04
NCT00775359
2002-10
NCT00775827
2002-12
NCT00543647
2003-03
NCT00006412
2003-05
NCT00304993
2005-02
14 further recorded trials
NCT00169559
2005-04
NCT00361751
2005-05
NCT00076518
2005-09
NCT00139061
2006-05
NCT00813527
2007-01
NCT00246636
2007-03
NCT00251680
2007-05
NCT00745407
2008-08
NCT01109758
2008-08
NCT00459745
2009-07
NCT00809068
2009-10
NCT02306889
2010-04
NCT02306902
2010-04
NCT00552747
2011-01
Q10
At the median, Fenofibrate's trials enrolled 60 people — anything larger?
Median enrolment
60
Largest enrolment
10251
Registered trials counted
134
Q11
What do 1659 spontaneous reports say about Fenofibrate — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Fenofibrate appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 1659 reaction mentions were counted: rhabdomyolysis 249; myalgia 244; drug interaction 220; drug hypersensitivity 204. open-targets-adr · CHEMBL672 · 2026-06-24
Show the evidence
rhabdomyolysis
249
myalgia
244
drug interaction
220
drug hypersensitivity
204
blood creatine phosphokinase increased
150
pancreatitis acute
133
4 more recorded rows
blood creatinine increased
126
renal failure acute
121
high density lipoprotein decreased
109
alanine aminotransferase increased
103
recorded 2026-06-24 · last checked 2026-09-04
Q12
Fenofibrate and CYP1A2, CYP2A6 and CYP2C19: shared by which compounds?
CYP1A2, CYP2A6 and CYP2C19 appear in Fenofibrate's recorded interaction sentences, 8 in all. openfda-label+europepmc · 2026-08-30
Interpretation pharmacokinetics
Show the evidence
CYP1A2pharmacokinetics
Drug Interaction Studies In vitro studies using human liver microsomes indicate that fenofibrate and fenofibric acid are not inhibitors of cytochrome (CYP) P450 isoforms CYP3A4, CYP2D6, CYP2E1, or CYP1A2.
CYP2A6pharmacokinetics
They are weak inhibitors of CYP2C8, CYP2C19 and CYP2A6, and mild-to-moderate inhibitors of CYP2C9 at therapeutic concentrations.
CYP2C19pharmacokinetics
They are weak inhibitors of CYP2C8, CYP2C19 and CYP2A6, and mild-to-moderate inhibitors of CYP2C9 at therapeutic concentrations.
CYP2C8pharmacokinetics
They are weak inhibitors of CYP2C8, CYP2C19 and CYP2A6, and mild-to-moderate inhibitors of CYP2C9 at therapeutic concentrations.
CYP2C9pharmacokinetics
They are weak inhibitors of CYP2C8, CYP2C19 and CYP2A6, and mild-to-moderate inhibitors of CYP2C9 at therapeutic concentrations.
CYP2D6pharmacokinetics
Drug Interaction Studies In vitro studies using human liver microsomes indicate that fenofibrate and fenofibric acid are not inhibitors of cytochrome (CYP) P450 isoforms CYP3A4, CYP2D6, CYP2E1, or CYP1A2.
2 more recorded rows
CYP2E1pharmacokinetics
Drug Interaction Studies In vitro studies using human liver microsomes indicate that fenofibrate and fenofibric acid are not inhibitors of cytochrome (CYP) P450 isoforms CYP3A4, CYP2D6, CYP2E1, or CYP1A2.
CYP3A4pharmacokinetics
Drug Interaction Studies In vitro studies using human liver microsomes indicate that fenofibrate and fenofibric acid are not inhibitors of cytochrome (CYP) P450 isoforms CYP3A4, CYP2D6, CYP2E1, or CYP1A2.
recorded 2026-08-30 · last checked 2026-09-04
Q13
Was Fenofibrate studied with fasting and exercise?
fasting and exercise are named in Fenofibrate's label sentences: "Fasting plasma samples from a subset of 542 participants in the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) trial were subjected to mass spectrometry." openfda-label+europepmc · 2026-08-30
2 recorded statements; fasting, exercise
Show the evidence
fasting
Fasting plasma samples from a subset of 542 participants in the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) trial were subjected to mass spectrometry.
exercise
Subjects were randomized into five treatment groups: usual care (group 1); low-saturated-fat diet and exercise (D/E; group 2); D/E + fenofibrate (group 3); D/E + niacin (group 4); or D/E + fenofibrate + niacin (group 5).
recorded 2026-08-30 · last checked 2026-09-04
Q14
What is recorded about Fenofibrate and AMPK?
"Furthermore, fenofibrate activated the AMPK/PGC-1α/PPARα pathway, suppressed the aberrant upregulation of the fatty acid transporters CD36 and FATP4, and restored the expression of key fatty acid oxidation-related enzymes, including CPT1A, CPT2, and ACOX1." — where Fenofibrate and AMPK appear together. Europe PMC · pathway abstract search · 2026-07-13
"Furthermore, fenofibrate activated the AMPK/PGC-1α/PPARα pathway, suppressed the aberrant upregulation of the fatty acid transporters CD36 and FATP4, and restored the expression of key fatty acid oxidation-related enzymes, including CPT1A, CPT2, and ACOX1."
mTORPMID 42302925
"The anti-tumor mechanisms of fenofibrate involve both PPARα-dependent pathways through direct regulation of PPARα and associated lipid metabolic enzymes, and PPARα-independent pathways, such as inhibition of the Akt/mTOR, TNF-α/NF-κB, and Cx43/EGF/ERK1/2 signaling axes."
AMPKPMID 41602450
"Fenofibrate improves endothelial-dependent relaxation and NO production in HFD-induced obese mice, likely through activation of the LKB1/AMPK/Akt pathway."
autophagy
PMID 41602117
"We evaluated effects of fenofibrate, a peroxisome proliferator-activated receptor α (PPARα) agonist, on <i>M. bovis</i> infection, using both bovine mammary epithelial cells and a murine mastitis model. <i>In vitro</i> analyses assessed autophagy, nuclear Transcription Factor EB (TFEB) and Transcription Factor E3 (TFE3) translocation, cholesterol metabolism, and bacterial localization, whereas…"
PMID 41602117
"Fenofibrate enhanced autophagic flux via upregulation of LC3B and LAMP2, promoted nuclear translocation of TFEB and TFE3, and reduced intracellular cholesterol by repressing 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase (HMGCR) and Sterol Regulatory Element-Binding Transcription Factor 2 (SREBF2) while increasing Acetyl-Coenzyme A Acetyltransferase 1 (ACAT1) expression."
PMID 41602117
"Fenofibrate enhanced defense capability of mammary epithelial cells against <i>M. bovis</i> infection through a dual mechanism-promoting autophagy and regulating cholesterol homeostasis-thereby reducing bacterial survival and protecting tissues from damage."
AMPKPMID 39575188
"The serum levels of silent information regulator 1 (SIRT1), NOD-like receptor protein 3 (NLRP3), and adenosine monophosphate activated protein kinase (AMPK), as well as fecal calprotectin levels were examined to determine the biological effect of fenofibrate."
sirtuinPMID 39575188
"The serum levels of silent information regulator 1 (SIRT1), NOD-like receptor protein 3 (NLRP3), and adenosine monophosphate activated protein kinase (AMPK), as well as fecal calprotectin levels were examined to determine the biological effect of fenofibrate."
mTORPMID 40887616
"This study aimed to investigate the growth-inhibitory effects of fibrate lipid-lowering drugs on bladder cancer cells and their underlying mechanisms, with a focus on exploring how fenofibrate (FNF) exerts antitumor effects by regulating mitochondrial function, the AMPK/mTOR signaling pathway, and the immune regulatory molecule CD276."
sirtuin
PMID 39757615
"Notably, treatment of fenofibrate dramatically activated the sonic hedgehog (SHH) and sirtuin-1 (SIRT1)."
PMID 39757615
"Furthermore, the inhibition of SHH or SIRT1 mitigated the anti-inflammatory effects of fenofibrate in IMG microglial cells."
mTORPMID 33984335
"Fenofibrate treatment activated autophagy and TFEB/TFE3 and reduced hepatic fat accumulation in an mTOR-independent manner."
recorded 2026-07-13 · last checked 2026-09-04
Where it is registeredIdentifiers, relations and other names
ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Europe PMC — metadata only, under the recorded legal gate · Open Targets 26.06 — CC0 · derived from this page's own recorded fields; no external licence · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 5 required field(s) not terminal: Why people use it, Best-supported result, Most important common problem, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 11 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.